KUBACKOVA, Katerina, Zbyněk BORTLÍČEK, Tomáš PAVLÍK, B. MELICHAR, Z. LINKE, P. POKORNA, Rostislav VYZULA, J. PRAUSOVA a T. BUCHLER. Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry. Targeted Oncology, Dordrecht: Springer, 2015, roč. 10, č. 3, s. 385-392. ISSN 1776-2596. doi:10.1007/s11523-014-0343-8.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
Autoři KUBACKOVA, Katerina (203 Česká republika), Zbyněk BORTLÍČEK (203 Česká republika, garant, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), B. MELICHAR (203 Česká republika), Z. LINKE (203 Česká republika), P. POKORNA (203 Česká republika), Rostislav VYZULA (203 Česká republika), J. PRAUSOVA (203 Česká republika) a T. BUCHLER (203 Česká republika).
Vydání Targeted Oncology, Dordrecht, Springer, 2015, 1776-2596.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Nizozemsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 3.197
Kód RIV RIV/00216224:14110/15:00083987
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1007/s11523-014-0343-8
UT WoS 000360766400007
Klíčová slova anglicky Renal cell carcinoma; Metastasis; Targeted therapy; Outcomes; First-line therapy
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 24. 9. 2015 16:32.
Anotace
The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70 % were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15 % of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time a parts per thousand currency sign1 year from diagnosis to first-line systemic treatment, performance status a parts per thousand yen2, low hemoglobin, and LDH > 1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.
VytisknoutZobrazeno: 26. 10. 2020 12:25